业绩连续三年下滑 悦康药业“救火式”赴港上市?

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitiveness and international brand image while diversifying its financing channels [1][2]. Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. was established in 2001 and is headquartered in Beijing, focusing on new drug research and development, production, distribution, and international trade [2]. - The company has developed nine core R&D platforms, including nucleic acid drugs, peptide drugs, traditional Chinese medicine innovation, and high-end chemical drugs [2]. Group 2: Financial Performance - The company has faced challenges with its fundraising projects, with a total of 2.192 billion yuan raised in its IPO, which has not led to sustained growth due to project delays [2][4]. - Yuyuan Pharmaceutical's net profit has declined for three consecutive years from 2022 to 2024, with decreases of 38.53%, 44.87%, and 33.05% respectively [4]. - In the first three quarters of 2025, the company reported total revenue of 1.759 billion yuan, a year-on-year decrease of 41.20%, and a net loss of 148 million yuan compared to a profit of 210 million yuan in the same period last year [6]. Group 3: Recent Developments - The company announced plans to raise up to 300 million yuan through a private placement to support its main business and supplement working capital [3]. - Yuyuan Pharmaceutical's core product, Ginkgo biloba extract injection, faced controversy over pricing, leading to a significant revenue drop of 36% in Q4 2024 and a net loss of 86.01 million yuan [3]. - The company's major shareholder, the Wei family, is facing issues with forced selling of shares, with 26.5 million shares auctioned for a total of 486 million yuan [7].